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Aim: The survival of patients with malignant pleural mesothelioma (MPM) who do not seek
treatment ranges from 4 to 12 months. To date, the optimal procedure for resection of ma-
lignant pleural mesothelioma is controversial, extrapleural pneumonectomy has been
most consistently associated with long-term survival and has provided the most radical cy-
toreduction; but, unfortunately, not all patients qualify for this invasive surgical approach.
Methods: Between 1992 and 2000, 64 patients underwent pleurectomy as a palliative treat-
ment for MPM. This retrospective study evaluates the operative outcome and the impact of
some prognostic factors on patients’ survival. Preoperative evaluation included chest
X-ray, CT and/or MRI. Diagnosis was made by pleural biopsy via needle, open, or VATS
biopsy. The Kaplan–Meier curve and the Log-Rank test were used to analyze the data.
Results: The median age of the study group was 65 (with a range of 29–84 years). Thirty-six
patients had epithelial histology, and 28 patients had sarcomatoid or mixed type (e.g., epi-
thelialþ spindle, epithelialþ sarcomatoid). The 30-day mortality rate was 3.1%. The overall
survival rate was 43%, 28%, and 10% at 1, 2, and 3 years, respectively. The overall median
survival was 9.4 months (ranging from 1.15 to 52.7 months). The overall median survival
with epithelial histology (n¼ 36, 56%) was 21.7 months (with a range of 1.4–52.7 months)
versus 5.8 months (with a range of 1.15–18.3 months) for the sarcomatoid or mixed type
(n¼ 28, 44%), p¼ 0.0001. The morbidity included atrial fibrillation (n¼ 5), wound infection
(n¼ 2), prolonged intubation (longer than 24 h, n¼ 8), reintubation for respiratory failure
(n¼ 2), pulmonary emboli (n¼ 1), UTI (n¼ 16), DVT (n¼ 5), MI (n¼ 4), and postoperative
bleeding (n¼ 7). Univariant analysis demonstrated that the only prognostic factors influ-
encing survival in our series was the histologic type. Age, gender, and the affected side
of the lung did not affect the median survival.
Conclusion: Our results show that pleurectomy can be performed as a means of palliation
for advanced-stage disease with a low mortality rate and may, in fact, improve survival
in patients with epithelial subtype as compared with historical controls in the literature
with no surgical intervention.
ª 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.eragi-Miandoab).
al Associates Ltd. Published by Elsevier Ltd. All rights reserved.
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Fig. 1 – Overall survival after pleurectomy for malignant
pleural mesothelioma. Overall survival: N[ 64,
median[ 9.4 months; 1 year[ 43%, 2 year[ 28%, 3
year[ 10%.Malignant Pleural mesothelioma (MPM) is an extremely ag-
gressive tumor originating from mesothelial cells. The major-
ity of patients with MPM typically present at an advanced
stage.1–4 The local tumor recurrence is the main culprit for
morbidity and mortality in this patient population and most
of patients die as a result of the primary lesion invading local
organs.2,3
Current surgical therapy for MPM is extrapleural pneumo-
nectomy (EPP) followed by adjuvant chemotherapy and radia-
tion to the hemithorax. However, tumor invasion into
mediastinal structures, an inadequate cardiopulmonary re-
serve, and poor performance status are major limiting factors
for an EPP.5,6 For this group of patients, pleurectomy offers
a palliative option that removes most of the pleura-based tu-
mor while preserving the lung. Palliative pleurectomy pro-
vides an incomplete tumor resection, but the resulting
pleurodesis provides some relief from pleural effusions.7–9
Historically, the indication for pleurectomy has been an
early-stage disease. However, convincing data showing pro-
longed survival after EPP made this approach the preferred
therapy for MPM in some centers. Pleurectomy is offered to
patients with more advanced disease when a radical debulk-
ing cannot be performed.1,2,4 Further, compromised perfor-
mance status in some patients makes them an inadequate





We identified 64 patients (55 males and 9 females) who had
undergone pleurectomy followed by adjuvant chemotherapy
(cisplatin/carboplatin/paclitaxel) and radiation to the hemi-
thorax (30 Gy) as palliative treatment for MPM at Brigham
and Women’s Hospital between 1992 and 2000. The objective
of this retrospective study is to review the efficacy and safety
of pleurectomy in patients with malignant pleural mesotheli-
oma and to assess the mean survival of patients and the effi-
cacy of pleurectomy in improving survival for each histologic
type. The Social Security Death Index and follow up in the hos-
pital were used to verify the patients’ survival. However, in
a few cases, the patients or their relatives needed to be con-
tacted by phone or mail. The Kaplan–Meier survival curve
and the Log-Rank test were used to analyze the data. The
study was approved by Institutional Review Board at Brigham
and Women’s Hospital and Dana Farber Cancer Institute.0
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Fig. 2 – Survival by histology: Redline: mixed (28;
median[ 5.8 months), Blue line: epithelial (36;
median[ 21.7 months), p< 0.0001.3. Results
The median age of the study group was 65 (with a range of
29–84 years). All patients had advanced-stage disease (i.e.,
Butchart stages II–III; six patients had stage IV disease) with
compromised cardiopulmonary function. Five patients under-
went attempted EEP; however, the tumor was found unresect-
able and a pleurectomy was performed. A chest wall resectionhad to be performed in six patients. One patient had thoraco-
scopic (VATS) pleurectomy.
Thirty-six patients (56%) had epithelial histology, and 28
patients had sarcomatoid or mixed (i.e., epithelialþ spindle,
epithelialþ sarcomatoid). The right to left ratio was 37/27.
The overall survival was 43%, 28%, and 10% at 1, 2, and 3 years,
respectively (Fig. 1). The overall median survival was 9.4
months, 21.7, and 5.8 months; for epithelial, sarcomatoid
and/or mixed type, respectively (Fig. 2). The 30-day mortality
rate was 3.1%. One patient died in the hospital after aspiration
pneumonia. The histologic type was the only significant prog-
nostic factor in our small series. Other factors such as age,
gender, and the affected side of lung did not have any impact
on survival and postoperative outcome.












Prolonged intubation >24 h 8
Wound infection 2
Postoperative bleed (>400) 7
Mean hospital stay SD (days) 10.8 6.2
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included atrial fibrillation in five patients, myocardial infarc-
tion (ECG change and elevated cardiac enzymes) in four pa-
tients, and pulmonary emboli in one patient. Eight patients
had postoperative respiratory failure and had to be kept intu-
bated longer than 24 h, which included two patients who had
to be reintubated for respiratory difficulty. Postoperative
bleeding (>400 ml) from the chest tube was noticed in seven
patients; none of the patients needed exploration for bleeding.
Other minor postoperative complications included: wound in-
fection (n¼ 2), urinary tract infection (n¼ 16), and deep vein
thrombosis (n¼ 5). Two patients had persistent air leak andTable 2 – Current data in literature showing the survival after
mesothelioma
Series n Age Stage of
disease
Mortality (%
Achatzy et al.11 118 55.8 – 6
Brancatisano et al.6 45 63 Early 2
Soysal et al.12 100 41 I and II 1
Pass et al.25 39 – – 2
Aziz et al.13 47 57 – 0
de Vries et al. 14 29 57 I and II 3.8




Martin-Uncar et al.15 51 62.5 Advanced 7.8
Lucchi et al. 26 49 61 IMIG stage II–III 0were discharged home with a Heimlich valve. One patient
had chyle leak, and the thoracic duct was ligated in the oper-
ating room. One patient developed Oglivie’s syndrome. The
overall mean hospital stay was 10.8 6.2 days.4. Discussion
The treatment aim in performing pleurectomy should be
debulking of the tumor, drainage of the effusion, decortica-
tion, re-expansion of the lung, and pleurodesis for symptom
relief.10 The mortality of this procedure is low (1.5–5%) with
a median survival ranging between 9.0 and 18.3 months (Table
2). In most of the published series, pleurectomy has been per-
formed in patients with early-stage disease (Table 2).6,11–15 Our
series represents a patient population that generally has ad-
vanced disease. The majority of our patients were older
(67.3 13 years) and multimorbid with cardiopulmonary com-
promise. Further, a high percentage of patients in this series
had non-epithelial histology (44%). Nevertheless, pleurectomy
could be performed with low perioperative mortality (3.1%).
Merritt et al.16 reported a series with 101 patients with ma-
lignant pleural mesothelioma who underwent palliative ther-
apy only. The average age in Merritt et al.’s series16 was
similar to our patient population: 65 and 67.3 years, respec-
tively. Median survival was 7 months in epithelial type, 2.7
months in sarcomatous, and 8.5 months in mixed type;
none of the performed palliative measures could prolong the
survival. The overall median survival in our series was 9.4
months (ranging from 1.15 to 52.7 months), 21.7 months forpleurectomy in patients with malignant pleural
) Median survival
(months)
Limitations of the study
9.2 2-Year survival 10.8%, 5 year survival 4.1%,
no information about stage, 118
pleurectomies, mean survival for 222
16 No stage, no periop mortality, 2-year
survival 21%
17 Limited follow up.
14.5 No age or stage of disease
14
9 Median survival for epith type 12, for
sarcoma 6.5, mixed 5 months, Butchart I, II
49, III 9 patients
29.9 The median survival is reported for
pleurectomy combined with 118 EPP
cases. No difference in survival was noted




7.2 Pleurectomy was performed per VATS, 1
year survival rate 31%.
Stage II 31 (1) Intrapleural preoperative interleukin 2
(2) Postoperative epidoxorubicin, IL-2,
adjuvant radiotherapy (30 Gy)
Stage III 21 (3) Systemic chemotherapy (cisplatin and
gemcitabine)
(4) Long-term sub-cutaneous IL-2
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months), and 5.8 months for sarcomatoid and/or mixed type
histology (ranging from 1.15 to 18.3 months, n¼ 28, 44%,
p¼ 0.0001). Our data demonstrated a significantly better sur-
vival after pleurectomy compared to palliative care. Addition-
ally, a subset of patients with epithelial histology had a major
improvement in survival. The epithelial histology was the
only independent prognostic factor for favorable outcome in
our series as well as in Merritt’s series.16 Similar findings
have been noted by other authors.9,17,18 Other studies have
reported comparable survival in conservatively managed pa-
tients.19,20 The survival in some series varies from 5.1
months19 to 9 months20; however, different time frames cho-
sen to describe the survival might explain the significant
differences in survival of MPM patients. Some authors calcu-
lated the survival from the time of established diagnosis as
well as onset of symptoms while others calculated the sur-
vival from the time when the patient has first therapy or sur-
gical intervention. The median survival with supportive care
in Law et al.’s21 series was 18 months from the onset of symp-
toms in a group of patients who received supportive care only
while Hulks et al. reported a median survival of 7.5 months
after the patients received medical attention.22
Halstead et al.23 demonstrated a clear survival benefit for
pleurectomy (VATS) compared to a nonoperative control group
(VATS biopsy only; 416, 127 days, respectively, p< 0.001), with
51 and 28 patients in each group, respectively. The median tu-
mor stage in their series was International Mesothelioma In-
terest Group (IMIG) stage 3. Their analysis demonstrated that
early stage ( p< 0.001), absence of preoperative fever
( p¼ 0.03) and surgery (P/D) ( p< 0.001) are independent predic-
tors of favorable outcome. The authors recommended VATS
pleurectomy as a safe approach to improve patients’ survival.23
Rush et al.9 studied factors that influenced the outcome
after resection of MPM in 231 patients, EPP in 115 patients
and P/D in 59 patients. Among patients having EPP or P/D,
142 patients received adjuvant therapy. The median survival
for stage I tumors was 29.9 months, for stage II was 19 months,
for stage III was 10.4 months, and for stage IV was 8 months.
The authors did not differentiate between pleurectomy and
EPP in regards to overall survival; however, they concluded
that there is no difference in survival between two surgical ap-
proaches. The stage of disease, histology, gender, and adju-
vant therapy had an impact on survival.9
Ceresoli et al.24 reviewed 121 cases of MPM. Histologic type
was epithelial in 88 patients (73%), sarcomatous in 21 (17%),
and mixed in 12 (10%). The overall median survival was 10.5
months. The 1-, 2-, and 3-year survival was 40%, 17%, and 8%,
respectively. A poor performance status, non-epithelial histol-
ogy, and advanced disease were associated with poor survival.
Patients receiving any therapy survived longer than patients
treated with supportive care only (p¼ 0.0004). Therapy had no
impact on survival in patients with sarcomatoid MPM nor did
poor performance status as confirmed in our series.24 Martin–
Uncar et al.15 reported that debulking surgery/pleurectomy
has a beneficial role in symptom control for unresectable
MPM and recommended that this approach should be reserved
for those patients who present with epithelial cell type.15
Recently, Flores et al.27 published a large multicenter study
(n¼ 663), which compared the EPP versus pleurectomy inmanagement of patients with MPM. Major predictors of prog-
nosis were stages of the disease, histology, EPP versus pleurec-
tomy, multimodality therapy versus surgery alone, and
gender. The authors reported mortality of 7% and 4% for EPP
and pleurectomy, respectively. The authors reported a better
survival after EPP than pleurectomy; however, they suggested
that the results might be biased secondary to various con-
founders including selection bias. The approach should be in-
dividualized to each patient’s stage of disease, comorbidities,
and type of multimodality therapy and patient’s performance
status. Further, traditionally, patients with early disease have
received pleurectomy and EPP has been preserved to extended
disease, which might explain the survival benefit for patients
after pleurectomy. A recent series from Mayo Clinic (n¼ 285)
demonstrated an overall median survival of 10.7 and 16
months; for pleurectomy and EPP, respectively. One-, 2-, and
3-year survival after extrapleural pneumonectomy was 61%,
25%, and 14%, respectively. The authors concluded that EPP
can be performed with a similar 30-day mortality as pleurec-
tomy/decortication. EPP was found to have high morbidity
and a 3-year survival of only 14%.28 Okada et al.29 reported
similar survival after EPP in a series of 87 patients who under-
went EPP or pleurectomy. Operative mortality was 3.2% for EPP
and none for P/D. The median and 3-year survivals after EPP
were 13 months and after pleurectomy 17 months. Age, non-
epithelial histology, stage of the disease were significant inde-
pendent prognostic factors.29 Although pleurectomy seems to
be an acceptable approach for early-stages disease, an EPP can
remove most of the tumor and might provide a more radical
debulking and extend the survival significantly. This has
been supported by other authors recently.28,29
Postoperative complications in our series are in concert
with the published data in the literature.5,6 The major morbid-
ity included AF in five patients (7.8%) and postoperative myo-
cardial infarction in four patients (6%). Table 1 demonstrates
the postoperative complications in our series stratified by ma-
jor and minor complications.5. Limitation of the study
A few of the major limitations of our series are the retrospec-
tive nature of the study, limited number of patients, and lack
of control group; however, we tried to compare our data with
available data in the literature.6. Conclusions
Our results show that pleurectomy can be performed as
a means of palliation with an acceptable mortality and mor-
bidity, and may improve the survival in patients with epithe-
lial subtype. The results in our series demonstrate mortality,
morbidity, and median survival, which are comparable with
published series with advanced disease. A debulking of tumor
followed by chemotherapy and radiation seems to have a clear
advantage in comparison with supportive care only. Pleurec-
tomy should be considered in patients with compromised per-
formance status, when an EPP cannot be performed. However,
a randomized trial would possibly demonstrate the survival
i n t e rn a t i o n a l j o u rn a l o f s u r g e r y 6 ( 2 0 0 8 ) 2 9 3 – 2 9 7 297advantage of active treatment including pleurectomy and
extrapleural pneumonectomy. Our results can serve as base-
line data and new therapeutic approach can be compared
with our and some other data in the literature to be evaluated
for their survival advantage.
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